Pharmacogenomics of Drug Safety in Multiple Sclerosis
Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment
1 other identifier
observational
300
1 country
5
Brief Summary
To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2010
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 4, 2010
CompletedFirst Posted
Study publicly available on registry
May 6, 2010
CompletedStudy Start
First participant enrolled
June 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedJanuary 14, 2026
January 1, 2026
14.9 years
May 4, 2010
January 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Experienced an adverse drug reaction or not?
No specified time frame
Study Arms (2)
Case
MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
Control
MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
Eligibility Criteria
Multiple sclerosis (MS) patients attending MS clinics located at the University of British Columbia Hospital, Winnipeg Health Sciences Centre, Dalhousie (Halifax, Nova Scotia) MS clinic, London Health Sciences Centre (London, ON) and Hôpital Notre-Dame (Montréal). Participants must have definite MS (Poser or McDonald criteria), with a relapsing-remitting or secondary-progressive disease course, registered at one of the above MS Clinics and prescribed a beta-interferon as an immunomodulatory drug for MS.
You may qualify if:
- definite MS (Poser or McDonald criteria)
- relapsing-remitting or secondary-progressive disease course
- Prescribed a beta-interferon as their immunomodulatory drug for MS
You may not qualify if:
- primary-progressive MS
- an elevated liver test result within 6 months of starting beta-interferon treatment
- presence of a co-morbidity that is a known risk-factor for liver injury
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of British Columbialead
- Canadian Institutes of Health Research (CIHR)collaborator
- Canada Foundation for Innovationcollaborator
- Genome Canadacollaborator
- British Columbia Clinical Genomics Networkcollaborator
Study Sites (5)
MS Clinic UBC Hospital
Vancouver, British Columbia, V6T 2B5, Canada
Winnipeg Health Sciences Centre
Winnipeg, Manitoba, Canada
Dalhousie MS Research Unit
Halifax, Nova Scotia, Canada
London Health Sciences Centre MS clinic
London, Ontario, Canada
Hôpital Notre-Dame MS clinic
Montreal, Quebec, Canada
Biospecimen
Saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bruce Carleton
University of British Columbia
- STUDY DIRECTOR
Michael Hayden
University of British Columbia
- STUDY DIRECTOR
Helen Tremlett
University of British Columbia
- STUDY DIRECTOR
Anthony Traboulsee
University of British Columbia
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
May 4, 2010
First Posted
May 6, 2010
Study Start
June 1, 2010
Primary Completion
May 1, 2025
Study Completion
May 1, 2025
Last Updated
January 14, 2026
Record last verified: 2026-01